Regeneron And Sanofi Antibody Discovery Deal To End

Regeneron and Sanofi have decided to call it a day on their antibody discovery partnership that brought the world Praluent, Dupixent and Kevzara. Regeneron announced that the collaboration was winding down during its Q2 results, where investors were focused on Dupixent's launch progress.

Business parting ways
Not Quite A parting of the ways • Source: Shutterstock

The antibody drug discovery deal between Regeneron Pharmaceuticals Inc. and Sanofi that produced Praluent, Dupixent and Kevzara is to come to an end at the close of 2017, the US company said during its second-quarter results presentation. Regeneron reported a solid second quarter, but investors' eyes glanced over the strong performance for Eylea (aflibercept) to focus rather on how the recent launch of product Dupixent (dupilumab) in atopic dermatitis was faring.

Regeneron's total revenues for the three months ended June 30 were $1.47bn, up 21% on the same quarter last year....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip